Response and progression in recurrent malignant glioma

Απλή σελίδα τεκμηρίου
dc.contributor.authorHess, K. R.en
dc.contributor.authorWong, E. T.en
dc.contributor.authorJaeckle, K. A.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorLevin, V. A.en
dc.contributor.authorPrados, M. D.en
dc.contributor.authorYung, W. K.en
dc.date.accessioned2015-11-24T18:53:52Z
dc.date.available2015-11-24T18:53:52Z
dc.identifier.issn1522-8517-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18618
dc.rightsDefault Licence-
dc.subjectActuarial Analysisen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectAstrocytoma/drug therapy/mortality/radiotherapyen
dc.subjectBrain Neoplasms/*drug therapy/mortality/radiotherapyen
dc.subjectCarboplatin/administration & dosageen
dc.subjectCombined Modality Therapyen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectEflornithine/administration & dosageen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectGlioblastoma/drug therapy/mortality/radiotherapyen
dc.subjectGlioma/*drug therapy/mortality/radiotherapyen
dc.subjectHumansen
dc.subjectInterferon-beta/administration & dosageen
dc.subjectMaleen
dc.subjectMenogaril/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Local/*drug therapy/mortalityen
dc.subjectProcarbazine/administration & dosageen
dc.subjectPrognosisen
dc.subjectProportional Hazards Modelsen
dc.subjectTexas/epidemiologyen
dc.subjectTreatment Outcomeen
dc.subjectTretinoin/administration & dosageen
dc.titleResponse and progression in recurrent malignant gliomaen
heal.abstractIn this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11550320-
heal.journalNameNeuro Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ